Asset Details
Do you wish to reserve the book?
PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression
Do you wish to request the book?
PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression
2025
Overview
This research investigates the regulatory role of the transcription factor PU.1 in type 1 conventional dendritic cells (cDC1) and its therapeutic potential of modulating the nuclear factor kappaB (NF-κB) cells signaling pathway in non-small cell lung cancer (NSCLC). Utilizing single-cell transcriptome sequencing and comprehensive bioinformatics tools, including the CIBERSORT algorithm, we analyzed the immune cell landscape within NSCLC tissues. Our analysis revealed distinct NSCLC subtypes and delineated the developmental trajectories and functional distinctions of cDC1 cells. Key differentially expressed genes (DEGs) and pivotal functional modules within these cells were identified, highlighting PU.1 as a critical mediator underexpressed in NSCLC samples. Functionally, PU.1 demonstrated the induction of the NF-κB pathway, which led to inhibited tumor proliferation and enhanced activation of cDC1, thereby suggesting its role in tumor immune surveillance. In vivo models confirmed the suppressive effect of PU.1 on NSCLC progression, mediated through its influence on cDC1 functionality via the NF-κB pathway. These findings propose PU.1 as a promising target for NSCLC therapeutic strategies, emphasizing the importance of transcriptional regulators in the tumor microenvironment.
[Display omitted]
•Revealing the critical role of cDC1 in NSCLC progression.•Identifying PU.1 as a potential regulatory gene for NSCLC for the first time.•Demonstrating that PU.1 inhibits tumor cell growth via the NF-κB pathway.•Providing a new therapeutic target for NSCLC.•Conducting in-depth analysis using single-cell transcriptome sequencing.
Publisher
Elsevier B.V,Department of Gerontology,The First Hospital of China Medical University,Shenyang,110001,China%Department of Rheumatology and Immunology,The First Hospital of China Medical University,Shenyang,110001,China%Department of Oncology,Shengjing Hospital of China Medical University,Shenyang,110022,China%Center of Reproductive Medicine,Department of Obstetrics and Gynecology,Shengjing Hospital of China Medical University,Shenyang,110022,China,Xi'an Jiaotong University,Elsevier
